TABLE 2.
Lipid nanoparticles as vector for delivery of mRNA vaccine for the treatment of COVID‐19
| Candidate vaccine | Developer | Target | Status |
|---|---|---|---|
| 3 LNP‐mRNAs |
BioNTech/Fosun Pharma/Pfizer |
SARS‐CoV‐2 |
Phase ½ 2020‐001038‐36 |
| LNP‐encapsulated mRNA | Moderna/NIAID | SARS‐CoV‐2 | Phase 1/2 NCT04283461 |
| LNP‐encapsulated mRNA vaccine encoding S‐protein | Moderna | SARS‐CoV‐2 |
Phase 1 NCT04283461 |
| LNP‐encapsulated mRNA cocktail encoding VLP | Fudan university/Shanghai Jointing, University/RNAcare, Biopharma | SARS‐CoV‐2 | Pre‐clinical |
| LNP‐encapsulated mRNA encoding RBD |
Fudan university/Shanghai JioTong, University/RNAcare, Biopharma |
SARS‐CoV‐2 | Pre‐clinical |
| LNP‐encapsulated mRNA | University of Tokyo/Daiichi‐Sankyo | SARS‐CoV‐2 | Pre‐clinical |
| Liposome‐encapsulated mRNA | BIOCAD | SARS‐CoV‐2 | Pre‐clinical |
| LNP‐mRNA | Translate Bio/Sanofi Pasteur | SARS‐CoV‐2 | Pre‐clinical |